ALX Oncology Holdings Inc Ordinary Shares ALXO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
-
ALX Oncology to Present at Upcoming Investor Conferences in September
-
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Trading Information
- Previous Close Price
- $1.19
- Day Range
- $1.10–1.23
- 52-Week Range
- $0.86–2.66
- Bid/Ask
- $1.10 / $1.18
- Shares Outstanding
- 138.28M
- Market Cap
- $161.78M
- Volume/Avg
- 556,401 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 48
- Website
- https://www.alxoncology.com
Valuation
|
Metric
|
ALXO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.19 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ALXO
|
|---|---|
Quick Ratio | 9.43 |
Current Ratio | 9.71 |
Interest Coverage | −59.38 |
Quick Ratio
ALXO
Profitability
|
Metric
|
ALXO
|
|---|---|
Return on Assets (Normalized) | −60.12% |
Return on Equity (Normalized) | −81.94% |
Return on Invested Capital (Normalized) | −76.39% |
Return on Assets
ALXO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|ccjKz% | LOCK|rC$?$ | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|!<jtxr | LOCK|Z!z# | $83B | |||
| Moderna Inc
MRNA
| LOCK|Rv?cDnm | LOCK|><z | $80B | |||
| argenx SE ADR
ARGX
| LOCK|#JKYz^ | LOCK|<wL | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|b>?ttk | LOCK|y@% | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|cLQzd^p | LOCK|^>#^x | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|v!T@pdW> | LOCK|TMK#B | $28B | |||
| Incyte Corp
INCY
| LOCK|%S$khr | LOCK|mS? | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|<?J#Rjv | LOCK|VG | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|s%&lDrT | LOCK|@^> | $14B |
United States